An mRNA vaccine teaches your cells to make a harmless piece of a virus, triggering your immune system to build defenses without ever exposing you to the real infection. Unlike traditional vaccines that inject a weakened or inactivated virus, mRNA vaccines deliver a set of genetic instructions that your body follows temporarily, then discards. The technology gained worldwide attention during the COVID-19 pandemic, but the science behind it had been in development for over two decades.
How mRNA Vaccines Work
Every cell in your body already uses mRNA (messenger ribonucleic acid) as a middleman. Your DNA sends mRNA instructions to your cell’s protein-making machinery, which reads those instructions and builds the corresponding protein. mRNA vaccines borrow this natural process. They deliver a synthetic strand of mRNA that codes for a specific viral protein, most famously the “spike protein” found on the surface of the coronavirus.
Once the vaccine is injected into your arm, your cells take up the mRNA and start producing copies of that viral protein. The protein itself is harmless on its own. It can’t cause infection. But your immune system recognizes it as foreign and responds by producing antibodies, specialized proteins that latch onto the viral protein, flag it for destruction, and remember it for later. If you’re ever exposed to the actual virus, your immune system already has a blueprint for fighting it.
The mRNA never enters the nucleus of your cells, which is where your DNA is stored. It cannot alter your genetic code. Once your cells finish reading the instructions, they break the mRNA down within hours to days, just as they do with the mRNA your own body produces constantly.
The Lipid Nanoparticle Shell
Raw mRNA is fragile. Enzymes in your body would shred it before it ever reached a cell. To solve this, mRNA vaccines wrap the instructions inside tiny fat bubbles called lipid nanoparticles. These serve two purposes: they shield the mRNA from being destroyed in your bloodstream, and they help the mRNA slip through cell membranes. Think of it as a protective envelope that dissolves once the message is safely inside the cell.
Beyond the mRNA and its lipid shell, the remaining ingredients are straightforward. A typical formulation includes cholesterol (which stabilizes the fat bubble), salts and buffers that keep the solution at the right acidity, and sucrose, which acts as a stabilizer during freezing. There are no preservatives, no adjuvants, and no live virus in the vial.
How They Differ From Traditional Vaccines
Traditional vaccines come in several forms. Some use a killed version of the whole virus (inactivated vaccines). Others use a live but weakened version (live-attenuated vaccines). Both approaches introduce actual viral material so your immune system can learn from it. mRNA vaccines skip that entirely. Instead of growing and processing a virus in a lab, manufacturers synthesize the genetic instructions and let your own cells handle protein production.
This difference has practical consequences. Manufacturing mRNA is faster than growing batches of virus in cell cultures or eggs, which is why COVID-19 vaccines were developed in under a year once the virus’s genetic sequence was published. Updating an mRNA vaccine for a new variant means swapping out the genetic sequence, not restarting a complex biological production line.
The immune response also differs in some ways. Research in animal models has shown that mRNA vaccines tend to generate a stronger cell-mediated immune response compared to inactivated vaccines. This means they’re particularly effective at training not just antibody-producing cells but also the immune cells that directly attack infected cells.
Common Side Effects
Most side effects from mRNA vaccines are temporary signs that your immune system is responding. Injection-site pain is the most frequently reported reaction, affecting roughly 44 to 74 percent of recipients depending on the study. Fatigue and muscle aches are also common, reported in around 17 to 50 percent of people. Headache occurs in about 6 to 34 percent, chills in around 32 percent, and fever in roughly 18 percent. These reactions typically appear within a day or two of vaccination and resolve within 24 to 48 hours.
Serious reactions are rare. Anaphylaxis, a severe allergic reaction, occurs in approximately 1 in 100,000 doses. This is why vaccination sites monitor people for 15 minutes after the shot. Other uncommon events reported in studies include chest pain (about 1.9 percent in one cohort) and fainting (under 1 percent).
Why They Need Cold Storage
mRNA’s fragility doesn’t just affect what happens inside your body. It also creates logistical challenges before the vaccine reaches your arm. The Pfizer-BioNTech vaccine initially required ultra-cold storage at minus 60 to minus 80 degrees Celsius, with a shelf life of up to six months at those temperatures but only about five days in a standard refrigerator. Moderna’s vaccine was more forgiving, stable for up to six months at minus 20 degrees and up to 30 days refrigerated. At room temperature, both lasted only a matter of hours.
These requirements posed real challenges for distribution in rural areas and lower-income countries. Newer formulations have gradually improved stability. Some experimental platforms, like one developed by the Chinese company Walvax, achieved room-temperature stability for up to seven days, pointing toward a future where cold-chain logistics become less of a barrier.
Decades of Research Before COVID-19
The COVID-19 vaccines were not built from scratch in 2020. The foundational breakthrough came from biochemist Katalin Karikó and immunologist Drew Weissman, who published a key paper in 2005 showing how to modify mRNA so that it wouldn’t trigger a destructive inflammatory response when injected into cells. Their trick involved swapping in a modified building block (pseudouridine) that made synthetic mRNA more stable, more efficient at producing protein, and less likely to set off immune alarm bells before it could do its job.
By 2010, several biotech companies were already developing mRNA vaccines against Zika virus and MERS, a coronavirus cousin. When SARS-CoV-2 emerged, the platform was ready. In 2020, Moderna’s and Pfizer-BioNTech’s vaccines became the first mRNA vaccines ever approved for human use. Karikó and Weissman received the Nobel Prize in Physiology or Medicine in 2023 for their work.
Currently Approved mRNA Vaccines
As of early 2026, the FDA has licensed three mRNA vaccines for use in the United States: Comirnaty (Pfizer-BioNTech), Spikevax (Moderna), and a newer formulation called mNextSPIKE. All three target COVID-19. No mRNA vaccines for other diseases have reached full approval yet, though that is changing quickly.
mRNA Beyond COVID-19
The same platform that made COVID-19 vaccines possible is now being tested against cancer. Unlike infectious disease vaccines that train the immune system before exposure, cancer mRNA vaccines are designed to help the body recognize and attack tumors that already exist. They work by encoding proteins specific to a patient’s tumor, prompting the immune system to target cancer cells it had previously overlooked.
Clinical trials are underway for melanoma, colorectal cancer, head and neck cancers, certain blood cancers, and glioblastoma (an aggressive brain tumor). Several of these are in phase 2 trials, and at least one (for a rare eye cancer called uveal melanoma) has reached phase 3, the final stage before potential approval. Researchers are also exploring mRNA vaccines for influenza, RSV, and other infectious diseases where traditional vaccine approaches have struggled.